Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival

被引:5
作者
Masubuchi, Ken [1 ]
Imai, Hisao [1 ,2 ]
Wasamoto, Satoshi [3 ]
Tsuda, Takeshi [4 ]
Minemura, Hiroyuki [5 ]
Nagai, Yoshiaki [6 ]
Yamada, Yutaka [7 ]
Kishikawa, Takayuki [8 ]
Umeda, Yukihiro [9 ]
Shiono, Ayako [2 ]
Takechi, Hiroki [3 ]
Shiihara, Jun [6 ]
Kaira, Kyoichi [2 ]
Kanazawa, Kenya [5 ]
Taniguchi, Hirokazu [4 ]
Kaburagi, Takayuki [7 ]
Kagamu, Hiroshi [2 ]
Minato, Koichi [1 ]
机构
[1] Gunma Prefectural Canc Ctr, Div Resp Med, Ota, Japan
[2] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka, Japan
[3] Saku Cent Hosp Adv Care Ctr, Div Resp Med, Saku, Nagano, Japan
[4] Toyama Prefectural Cent Hosp, Div Resp Med, Toyama, Japan
[5] Fukushima Med Univ, Dept Pulm Med, Fukushima, Japan
[6] Jichi Med Univ, Saitama Med Ctr, Dept Resp Med, Saitama, Japan
[7] Ibaraki Cent Hosp, Div Resp Med, Kasama, Ibaraki, Japan
[8] Tochigi Canc Ctr, Div Thorac Oncol, Utsunomiya, Tochigi, Japan
[9] Univ Fukui, Dept Internal Med 3, Fac Med Sci, Eiheiji, Japan
关键词
atezolizumab; carboplatin; etoposide; overall survival; post-progression survival; SURROGATE END-POINTS; TUMOR RESPONSE; 2ND-LINE TREATMENT; PERFORMANCE; TOPOTECAN;
D O I
10.1111/1759-7714.14621
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The effect of first-line chemotherapy on overall survival (OS) may be significantly influenced by subsequent therapy for patients with extensive disease small cell lung cancer (ED-SCLC). Therefore, we evaluated the relationship between progression-free survival (PFS), post-progression survival (PPS), and OS of ED-SCLC patients treated with atezolizumab plus carboplatin and etoposide as first-line therapy. Methods We analyzed the data of 57 patients with relapsed ED-SCLC treated with atezolizumab plus carboplatin and etoposide (AteCE) as first-line chemotherapy between August 2019 and September 2020. The respective correlations between PFS-OS and PPS-OS following first-line AteCE treatment were examined at the individual patient level. Results Spearman's rank correlation analysis and linear regression analysis showed that PPS strongly correlated with OS (r = 0.93, p < 0.05, R-2 = 0.85) and that PFS moderately correlated with OS (r = 0.55, p < 0.05, R-2 = 0.28). Performance status at relapse (0-1/>= 2), number of cycles of atezolizumab maintenance therapy (<3/>= 3), and platinum rechallenge chemotherapy all significantly positively correlated with PPS (p < 0.05). Conclusions Upon comparing OS-PFS and OS-PPS in this patient population, OS and PPS were found to have a stronger correlation. These results suggest that performance status at relapse, atezolizumab maintenance, or chemotherapy rechallenge could affect PPS.
引用
收藏
页码:2776 / 2785
页数:10
相关论文
共 35 条
  • [1] Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease
    Ardizzoni, A
    Hansen, H
    Dombernowsky, P
    Gamucci, T
    Kaplan, S
    Postmus, P
    Giaccone, G
    Schaefer, B
    Wanders, J
    Verweij, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 2090 - 2096
  • [2] Baize N, 2020, LANCET ONCOL, V21, P1224, DOI 10.1016/S1470-2045(20)30461-7
  • [3] Bernhardt EB, 2016, CANCER TREAT RES, V170, P301, DOI 10.1007/978-3-319-40389-2_14
  • [4] Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
    Broglio, Kristine R.
    Berry, Donald A.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (23): : 1642 - 1649
  • [5] Small Cell Lung Cancer: Where Do We Go From Here?
    Byers, Lauren Averett
    Rudin, Charles M.
    [J]. CANCER, 2015, 121 (05) : 664 - 672
  • [6] PERFORMANCE AND PROGNOSIS IN PATIENTS WITH LUNG-CANCER
    CAPEWELL, S
    SUDLOW, MF
    [J]. THORAX, 1990, 45 (12) : 951 - 956
  • [7] Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
    Demedts, I. K.
    Vermaelen, K. Y.
    van Meerbeeck, J. P.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2010, 35 (01) : 202 - 215
  • [8] Second-line chemotherapy for relapsed small cell lung cancer
    Ebi, N
    Kubota, K
    Nishiwaki, Y
    Hojo, F
    Matsumoto, T
    Kakinuma, R
    Ohmatsu, H
    Sekine, I
    Yokosaki, M
    Gotoh, K
    Yamamoto, H
    Kodama, T
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (03) : 166 - 169
  • [9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [10] Current standards for clinical management of small cell lung cancer
    Farago, Anna F.
    Keane, Florence K.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (01) : 69 - 79